A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
2상
진행 중(모집 완료)
NCT04639219
| 대상 질환 | Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | AstraZeneca |
|---|
| 상태 | 진행 중(모집 완료) |
|---|
| 참여자 수 | 102 명 |
|---|
| 중재(약물) | Trastuzumab deruxtecan |
|---|
| 시작일 | 2020년 12월 30일 |
|---|
| 완료일 | 2023년 1월 25일 |
|---|
| 결과 공개일 | 2024년 2월 15일 |
|---|
요약
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted.
Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)
Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months) · percentage of participants
| T-DXd | 29.4 percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.